Fig. 1 · Structure

Documents & Downloads

Rutoside (Rutin)

Cat. No. A10815 CAS 153-18-4
Rutin is one of the phenolic compounds found in the invasive plant species Carpobrotus edulis and contributes to the antibacterial and antioxidant properties of the plant

In Stock

Publications for Rutoside

5 publications citing this product

  1. Sumayyah Saeed, .et al. , Int J Mol Sci, 2025, Jan 14;26(2):654 PMID: 39859369
  2. Filipe Kayodè Felisberto Dos Santos, .et al. , Biomass, 2024, 4(2), 217-242
  3. Rashmi Rawat, .et al. , Food Chemistry Advances, 2022, 1: 100092
  4. Jianwei Dou, .et al. , J Sep Sci, 2020, Dec 4 PMID: 33275824
  5. Booker A, .et al. , Phytomedicine, 2018, Feb 1;40:158-164 PMID: 29496168

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Bioactivity / Mechanism

Rutin (quercetin-3-rutinoside) inhibits PDI reductase activity in biochemical assays. Reported IC50 values were 6.1 μM in an insulin-reduction assay and 4.6 μM in a BD-SS fluorogenic assay. These estimates are assay-specific. A limited thiol-isomerase panel showed substantially less inhibition of the tested comparators than of PDI. [1,2]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Cellular Effect

Cell Line Activity Value Description Reference
A549 IC50 > 10 μM Cytotoxicity against human A549 cells after 48 hrs by SRB assay [PMID: 28165740]
BALB/3T3 IC50 > 164 μM Growth inhibition of BALB/c mouse cloned 3T3/A31 cells after 72 hrs by nigrosin assay [PMID: 10096863]
BMDC IC50 > 50 μM Inhibition of LPS-induced IL-12 p40 production in wild-type C57BL/6 mouse BMDC pretreated with compound for 1 hr before LPS treatment measured 16 hrs by ELISA [PMID: 25769817]
BMDC IC50 > 50 μM Inhibition of LPS-induced IL-6 production in wild-type C57BL/6 mouse BMDC pretreated with compound for 1 hr before LPS treatment measured 16 hrs by ELISA [PMID: 25769817]
BMDC IC50 > 50 μM Inhibition of LPS-induced TNF-alpha production in wild-type C57BL/6 mouse BMDC pretreated with compound for 1 hr before LPS treatment measured 16 hrs by ELISA [PMID: 25769817]
BT-549 IC50 > 10 μM Cytotoxicity against human BT549 cells after 48 hrs by SRB assay [PMID: 28165740]
BV-2 IC50 24.29 μM Antiinflammatory activity in mouse BV2 cells assessed as inhibition of LPS-induced nitrite production after 24 hrs by Griess assay [PMID: 28165740]
HEK293 EC50 1.2 μM Agonist activity at human NMU2R transfected in HEK293 cells after 7 hrs by luciferase reporter gene assay [PMID: 25262941]
K562 IC50 897 μM Induction of apoptosis in human K562 cells assessed as total apoptotic cells after 3 days by Annexin-V staining-based assay [PMID: 25496805]
L929 IC50 > 100 μM Cytotoxicity against mouse L929 cells after 5 days by MTS assay [PMID: 22743241]
L929 EC50 > 250 μM Inhibition of recombinant human TNF-alpha-induced cytotoxicity of mouse L929 cells assessed as survivality preincubated for 15 mins before TNFalpha addition measured after 24 hrs by [methyl-3H]thymidine incorporation assay [PMID: 9287415]
L929 EC50 250 μM Inhibition of recombinant human TNF-alpha-induced cytotoxicity of mouse L929 cells assessed as survivality preincubated for 15 mins before TNFalpha addition measured after 24 hrs by crystal violet staining [PMID: 9287415]
N9 IC50 > 100 μM Antineuroinflammatory activity in mouse N9 cells assessed as inhibition of LPS-induced nitric oxide production after 24 hrs by Griess assay [PMID: 28073678]
RAW264.7 IC50 15.07 μM Anti-inflammatory activity in Mus musculus (mouse) RAW264.7 cells assessed as inhibition of PMA-induced macrophages respiratory burst measured up to 30 min by chemiluminescence method 10.1007/s00044-013-0504-9
RAW264.7 IC50 27.5 μM Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production after 18 hrs by griess reaction analysis [PMID: 24679441]
RAW264.7 IC50 44.5 μM Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced TNF-alpha secretion after 18 hrs by sandwich ELISA [PMID: 24679441]
RD EC50 109.63 μM Antiviral activity against EV71 infected in human RD cells assessed as reduction in viral plaque formation after 1 hr by crystal violet staining method [PMID: 27776325]
SK-MEL-2 IC50 > 10 μM Cytotoxicity against human SK-MEL-2 cells after 48 hrs by SRB assay [PMID: 28165740]
SK-OV-3 IC50 > 10 μM Cytotoxicity against human SKOV3 cells after 48 hrs by SRB assay [PMID: 28165740]

19 records · Scroll to view more

Rutoside (Rutin) Research Summary

This section summarizes 3 in vitro studies and 1 in vivo study of Rutoside (Rutin) from 3 published references.

Rutoside (Rutin) In Vitro Studies

In washed human platelets, rutin reduced aggregation induced by the PAR4 agonist AYPGKF after a 15-minute incubation at 30 or 45 μM. In a separate washout comparison within the same experiment, removal of 60 μM rutin restored aggregation. These findings support a reversible antiplatelet effect under the tested conditions. [1]

PDI reductase inhibition and limited thiol-isomerase selectivity panel

Biochemical assay · Purified recombinant human PDI; insulin-reduction assay; immobilized PDI in SPR [1]

Rutin inhibited PDI reductase activity and bound immobilized PDI. Other tested vascular thiol isomerases showed little inhibition under the reported conditions; this panel does not establish proteome-wide selectivity.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
PDI-catalyzed insulin reductionIC50 6.1 μM (1.1–10.7 μM, 95% confidence interval)[1]
Binding to immobilized PDIKd 2.8 μM[1]
ERp5, ERp57, ERp72, thioredoxin and thioredoxin reductase comparisonqualitative Minimal inhibition compared with PDI at up to 30 μM[1]

Literature-Reported Treatment Conditions

Treatment concentration
Assay-dependent concentration series; selectivity panel 0.3, 3 and 30 μM. SPR analyte 0–100 μM. IC50 is an endpoint, not a treatment dose.
Exposure duration
Insulin reaction monitored for 30 minutes; SPR analyte perfusion 2 minutes.
Method
Insulin assay with 0.8 μM PDI, 0.1 mM insulin and 0.75 mM DTT at 23°C; SPR uses immobilized PDI.
Vehicle
Insulin assay control buffer; SPR PBS with 0.005% P20 and 0.5% DMSO.
Co-treatment
None; DTT is assay reducing reagent.
Reported limits
Final solvent composition for the insulin assay and replicate n for Figure 1B are not specified at the adopted main-text locations.
Methods and source locations

Compound reported in the paper: Rutin (quercetin-3-rutinoside); Compound label in the paper: Quercetin-3-rutinoside

Evidence concerns the reported parent compound. No equivalence of hydrate states, salt conversion or Adooq lot performance is asserted.

Results identification/selectivity; Figures 1B–C and 3A–B; Methods insulin reduction assay and SPR

PDI-catalyzed insulin reduction: Insulin aggregation absorbance at 650 nm; nonlinear regression. Figure 1B reports mean ± SD. — Results identification; Figure 1B

Binding to immobilized PDI: Surface plasmon resonance with reference-surface subtraction; duplicate concentration sensorgrams. — Results identification; Figure 1C; Methods SPR

ERp5, ERp57, ERp72, thioredoxin and thioredoxin reductase comparison: Figure 3A: insulin reduction, mean and SD of 3 independent determinations. Figure 3B: thioredoxin/thioredoxin reductase system ±30 μM rutin. — Results selectivity; Figure 3A–B

Reversible inhibition of PAR4-stimulated human platelet aggregation

Cell-based study · Washed human platelets, 2 × 10^8 platelets/ml [1]

Rutin reduced PAR4 agonist-induced aggregation. Removing rutin by washing restored aggregation, with a vehicle-plus-wash control supporting reversibility. Antibody RL90 served as a PDI-inhibition comparator; this experiment alone does not establish exclusive PDI mediation.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
AYPGKF-induced platelet aggregationqualitative Aggregation reduced with 30 and 45 μM rutin relative to vehicle[1]
Aggregation following compound removalqualitative Inhibition at 60 μM was reversed after washing[1]

Literature-Reported Treatment Conditions

Treatment concentration
30 or 45 μM in the inhibition comparison; 60 μM in the washout experiment.
Exposure duration
15-minute incubation before stimulation.
Method
Incubation at 37°C; stimulation with 50 μM PAR4 peptide AYPGKF; light transmission aggregometry.
Vehicle
PBS and 0.1% DMSO.
Co-treatment
No drug combination; AYPGKF is the activating stimulus, RL90 a separate comparator.
Reported limits
Donor count, biological replicate count and numerical effect estimates are not provided in Figure 4A–B/caption; no exact curve-derived values extracted.
Methods and source locations

Compound reported in the paper: Rutin (quercetin-3-rutinoside); Compound label in the paper: Quercetin-3-rutinoside

Evidence concerns the reported parent compound. No equivalence of hydrate states, salt conversion or Adooq lot performance is asserted.

Results platelet aggregation; Figure 4A–B; Methods platelet aggregation

AYPGKF-induced platelet aggregation: Light transmission aggregometry; anti-PDI RL90 comparator. — Figure 4A and caption; Results platelet aggregation

Aggregation following compound removal: Vehicle, rutin, vehicle followed by wash, and rutin followed by wash compared before agonist stimulation. — Figure 4B and caption; Results platelet aggregation

Rutin inhibition in a fluorogenic PDI reductase assay

Biochemical assay · Recombinant human wild-type PDI CC/CC, 45 nM; 10 μM bodipy-labeled L-cystine (BD-SS) [2]

Rutin produced concentration-dependent inhibition in a substrate system distinct from insulin. Isoquercetin was active, whereas quercetin showed only negligible inhibition at high concentration. The 4.6 μM estimate belongs to this assay and is not pooled with the earlier insulin-assay IC50.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
BD-SS reduction by PDI CC/CCIC50 4.6 μM[2]
Quercetin comparator inhibitioninhibition ~5% even at >100 μM quercetin[2]

Literature-Reported Treatment Conditions

Treatment concentration
Rutin concentration-response series; exact tested points not transcribed from logarithmic plot.
Exposure duration
Shared steady-state method: 10-minute compound–enzyme preincubation; rates assessed over 100–600 s.
Method
BD-SS fluorogenic reduction; shared steady-state buffer PBS pH 7.4, 2 mM EDTA and 10 μM DTT. Figure-specific enzyme concentration is 45 nM (not the general-method 30 nM).
Vehicle
Compounds dissolved in DMSO; final DMSO fraction not specified in the retrieved main manuscript.
Co-treatment
None; isoquercetin and quercetin are separate comparators.
Reported limits
No IC50 confidence interval or replicate n stated in Figure 4 caption. SI not retrieved. Final solvent fraction remains unknown.
Methods and source locations

Compound reported in the paper: Rutin (quercetin-3-rutinoside); Compound label in the paper: Rutin

Evidence concerns the reported parent compound. No equivalence of hydrate states, salt conversion or Adooq lot performance is asserted.

Figure 4A,E and caption; Methods Compounds and steady-state kinetics; Results glycosylation comparison

BD-SS reduction by PDI CC/CC: Fluorogenic reductase dose-response; 45 nM PDI and 10 μM BD-SS explicitly specified by Figure 4 caption. — Figure 4E and caption

Quercetin comparator inhibition: Separate aglycone comparator in the same assay; not a rutin result. — Figure 4E and caption

Rutoside (Rutin) In Vivo Studies

In a mouse vascular-injury model, intravenous rutin at 5 μg/g body weight reduced HRG fluorescence accumulation and preserved antithrombin signal at the injury site compared with vehicle. HRG fluorescence AUC fell by 57.3%. The reported sample sizes count thrombi rather than mice; these imaging endpoints do not establish clinical benefit. [3]

Rutin alters HRG and antithrombin incorporation at vascular injury sites

Animal study · Male wild-type C57BL/6-background mice, 8–16 weeks; laser-injured cremaster arterioles [3]

Rutin decreased HRG accumulation and preserved antithrombin fluorescence in parallel intravital readouts. These are injury-site protein-incorporation endpoints, not survival, clinical thrombosis or a demonstration of therapeutic benefit.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
HRG fluorescence area under the curve per thrombusreduction versus vehicle 57.3% (P = 0.0001)[3]
Antithrombin fluorescence AUC per thrombusqualitative with reported P Signal preserved/increased versus vehicle; P = 0.0001[3]

Conditions shared by the study groups

Route
Intravenous infusion
Frequency
Infused before vessel injury; repeat schedule not specified for rutin.
Treatment course
Acute intravital experiment; exact pretreatment interval not specified.
Vehicle
Vehicle control; composition not identified in the retrieved main-text locations.
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Rutin versus vehicle
5 μg/g body weight
Vehicle-treated mice; HRG and antithrombin assessed in parallel experiments.HRG fluorescence AUC decreased by 57.3% (P = 0.0001); antithrombin signal was preserved/increased relative to vehicle (Figure 5j: P = 0.0001).[3]
Rutin versus vehicle
Model: Male wild-type mice on a C57BL/6 background, 8–16 weeks; laser-injured cremaster arterioles
Reported limits: Mouse count per Figure 5 comparison and final vehicle composition are not specified in the retrieved main-text locations; reported n values count thrombi.
Methods and source locations

Compound reported in the paper: Rutin (quercetin-3-rutinoside); Compound label in the paper: Rutin

Evidence concerns the reported parent compound. No equivalence of hydrate states, salt conversion or Adooq lot performance is asserted.

Results extracellular PDI regulates HRG accumulation; Figure 5c–e,h–j; Methods Animals, intravital microscopy, data analysis

HRG fluorescence area under the curve per thrombus: Fluorescent anti-HRG intravital imaging; vehicle n = 31 thrombi, rutin n = 36 thrombi; mean ± SEM; two-tailed Mann–Whitney U test. — Results extracellular PDI regulates HRG accumulation; Figure 5c–e and caption

Antithrombin fluorescence AUC per thrombus: Fluorescent anti-antithrombin intravital imaging; vehicle n = 39 thrombi, rutin n = 38 thrombi; mean ± SEM; two-tailed Mann–Whitney U test. No exact fold change inferred from graph. — Figure 5h–j and caption; Results parallel antithrombin experiment

Rutin versus vehicle · Figure 5c–e,h–j; Methods Animals and intravital microscopy

Specifications

Manufacturer Adooq Bioscience
CAS Number 153-18-4
Formula C27H30O16
Molecular Weight 610.5
Synonyms Quercetin 3-rutinoside; Rutin trihydrate; Phytomelin; Birutan; Sophorin; Venoruton; Eldrin; Rutin
SMILES
C[C@H]1[C@@H]([C@H]([C@H]([C@@H](O1)OC[C@@H]2[C@H]([C@@H]([C@H]([C@@H](O2)OC3=C(OC4=CC(=CC(=C4C3=O)O)O)C5=CC(=C(C=C5)O)O)O)O)O)O)O)O

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 91 mg/mL (149.05 mM)
Water Insoluble
Ethanol 2 mg/mL (3.27 mM)

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Rutoside (Rutin) Research References

  1. [1] Jasuja R, Passam FH, Kennedy DR, et al. Protein disulfide isomerase inhibitors constitute a new class of antithrombotic agents The Journal of clinical investigation (2012). PMID: 22565308 DOI: 10.1172/jci61228 Source material
  2. [2] Ponzar N, Chinnaraj M, Pagotto A, et al. Mechanistic basis of activation and inhibition of protein disulfide isomerase by allosteric antithrombotic compounds Journal of thrombosis and haemostasis : JTH (2025). PMID: 39454880 DOI: 10.1016/j.jtha.2024.09.036 Source material
  3. [3] Lv K, Chen S, Xu X, et al. Protein disulfide isomerase cleaves allosteric disulfides in histidine-rich glycoprotein to regulate thrombosis Nature communications (2024). PMID: 38605050 DOI: 10.1038/s41467-024-47493-0 Source material

Publications

5 publications citing this product

  1. Sumayyah Saeed, .et al. , Int J Mol Sci, 2025, Jan 14;26(2):654 PMID: 39859369
  2. Filipe Kayodè Felisberto Dos Santos, .et al. , Biomass, 2024, 4(2), 217-242
  3. Rashmi Rawat, .et al. , Food Chemistry Advances, 2022, 1: 100092
  4. Jianwei Dou, .et al. , J Sep Sci, 2020, Dec 4 PMID: 33275824
  5. Booker A, .et al. , Phytomedicine, 2018, Feb 1;40:158-164 PMID: 29496168

Added to your cart

View Cart Checkout
Loading...